The efficacy and safety of an oral contraceptive containing chlormadinone acetate: Results of a pooled analysis of noninterventional trials in adult and adolescent women

Contraception

Volumn 84, Issue 4, 2011, Pages 390-401

  Schramm, Georg A K ^a   Schrah, Guido ^b  

^a GRÜNENTHAL GMBH   (Germany)

^b Factum Gesellschaft für Statistik   (Germany)

Author keywords

Adolescent; Adult women; Chlormadinone acetate ethinylestradiol; CME EE; Noninterventional trial; Pooled analysis

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; AGED; ARTICLE; BODY MASS; BREAKTHROUGH BLEEDING; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HUMAN; MENSTRUATION; META ANALYSIS; OBESITY; PATIENT COMPLIANCE; PEARL INDEX; PREGNANCY; SCORING SYSTEM; SEBORRHEA; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; WEIGHT CHANGE; WELLBEING;

ACNE VULGARIS; ADOLESCENT; ADULT; CHLORMADINONE ACETATE; CLINICAL TRIALS AS TOPIC; CONTRACEPTIVES, ORAL, COMBINED; DYSMENORRHEA; ETHINYL ESTRADIOL; FEMALE; GERMANY; HUMANS; MENSTRUAL CYCLE; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 80052796447     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.03.024     Document Type: Article

References (29)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
2. H. Jick, S.S. Jick, V. Gurewich, M.W. Myers, and C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593 (Pubitemid 26001840)
3. W.O. Spitzer, M.A. Lewis, L.A. Heinemann, M. Thorogood, and K.D. MacRae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ 312 1996 83 88
4. K.W. Bloemenkamp, F.R. Rosendaal, F.M. Helmerhorst, H.R. Büller, and J.P. Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 1995 1593 1596 (Pubitemid 26001841)
5. J.C. Dinger, L. Heinemann, and D. Kuhl-Habich The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation Contraception 75 2007 344 354 (Pubitemid 46551071)
6. G. Schramm, and D. Steffens Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study Clin Drug Invest 22 2002 221 231 (Pubitemid 34454609)
7. G. Schramm, and D. Steffens A 12-month evaluation of the CMA-containing oral contraceptive (Belara®): efficacy, tolerability and anti-androgenic properties Contraception 67 2003 305 312 (Pubitemid 36398516)
8. G. Schramm, and B. Heckes Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study Contraception 76 2007 84 90 (Pubitemid 47080979)
9. K. Bock, M.L. Heskamp, and G. Schramm Influence of chlormadinone acetate on dysmenorrhoea and other cycle related complaints Gyne 219-25 2008 8 [in German]
10. S. Anthuber, G.A. Schramm, and M.L. Heskamp Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study Clin Drug Investig 30 2010 211 220
11. M.L. Heskamp, and G. Schramm Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits Contraception 81 2010 49 56
12. B. Runnebaum, and T. Rabe Gynakologische Endokrinologie 1994 Springer, Heidelberg New York, NY 412 453
13. L. Speroff, and A. De Cherny Advisory board for the new progestin. Evaluation of a new generation of oral contraceptives Obstet Gynecol 81 1993 1034 1047 (Pubitemid 23168756)
14. S.L. Corson Efficacy and clinical profile of a new oral contraceptive containing norgestimate Acta Obstet Gynecol Scand 152 1990 25 31 (Pubitemid 20177241)
15. J.C. Dinger, M. Cronin, S. Möhner, I. Schellschmidt, T. Do Min, and C. Westhoff Oral contraceptive effectiveness according to body mass index, weight, age, and other factors Am J Obstet Gynecol 201 2009 263.e1 263.e9
16. S.H. O'Brien, E.E. Kaizar, M.A. Gold, and K.J. Kelleher Trends in prescribing patterns of hormonal contraceptives for adolescents Contraception 77 2008 264 269
17. R.D. Farmer, R.A. Lawrenson, C.R. Thompson, J.G. Kennedy, and I.R. Hambleton Population-based study of risk of venous thromboembolism associated with various oral contraceptives Lancet 349 1997 83 88 (Pubitemid 27023424)
18. R.D. Farmer, and T.D. Preston The risk of venous thromboembolism associated with low-dose estrogen oral contraceptives J Obstet Gynaecol 15 1995 195 200
19. B.B. Gerstman, J.M. Piper, D.K. Tomita, W.J. Ferguson, B.V. Stadel, and F.E. Lundin Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease Am J Epidemiol 133 1991 32 37
20. R.D. Farmer, R.A. Lawrenson, and J.C. Todd A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives Br J Clin Pharmacol 49 2000 580 590 (Pubitemid 30326558)
21. R.M. Ornstein, and M.M. Fisher Hormonal contraception in adolescents: special considerations Paediatr Drugs 8 2006 25 45
22. M.J. Rosenberg, and M.S. Waugh Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons Am J Obstet Gynecol 179 1998 577 582 (Pubitemid 28447229)
23. H.P. Zahradnik, J. Goldberg, and J.E. Andreas Efficacy and safety of the new antiandrogenic oral contraceptive (Belara®) Contraception 57 1998 103 109 (Pubitemid 28208481)
24. L. Heinemann, and J. Dinger Safety of a new oral contraceptive containing drospirenone Drug Saf 27 2004 1001 1018 (Pubitemid 39487064)
25. J.M. Foidart, P.J. Sulak, I. Schellschmidt, and D. Zimmermann Yasmin Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days Contraception 73 2006 34 40 (Pubitemid 41811186)
26. G. Bachmann, P.J. Sulak, C. Sampson-Landers, N. Benda, and J. Marr Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone Contraception 70 2004 191 198 (Pubitemid 39119980)
27. R.W. Rebar Combination oral contraceptives Curr Ther Endocrinol Metab 6 1997 275 280
28. T.R. Dunson, V.L. McLaurin, and E.L. Aguayo A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives Contraception 4 1993 515 525 (Pubitemid 23189696)
29. K. Fotherby Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg desogestrel Contraception 51 1995 3 12